Search for: "SANOFI-SYNTHELABO INC"
Results 1 - 20
of 45
Sort by Relevance
|
Sort by Date
18 Feb 2020, 4:00 am
Pfizer Canada ULC, 2020 FC 1, at para. 42. [3] See Sections 27(3)(b) and 28.3 of the Patent Act, RSC 1985, c P-4 [4] Burton Parsons Chemicals, Inc v Hewlett-Packard (Canada) Ltd, [1976] 1 SCR 555 at 563 [5] Apotex Inc v Sanofi-Synthelabo Canada Inc, 2008 SCC 61 at paragraph 37, [2008] 3 SCR 265; see also Bell Helicopter Textron Canada Limitée v Eurocopter, société par actions simplifiée, 2013 FCA 219 at paragraph 65; Mylan… [read post]
9 Nov 2017, 4:00 am
In that decision (Apotex Inc. v. [read post]
11 Sep 2015, 3:00 am
Inc.; and Sanofi-Synthelabo Inc. [read post]
10 Apr 2015, 3:00 am
Services Inc., and Sanofi-Synthelabo, Inc., engaged in unfair and deceptive marketing practices relating to the efficacy of Plavix, an anti-clotting prescription drug. [read post]
12 Dec 2014, 10:29 pm
" Sanofi-Synthelabo v. [read post]
17 Jun 2014, 6:15 pm
Sanofi-Synthelabo v. [read post]
13 Apr 2014, 8:59 am
Sanofi-Synthelabo Canada Inc., [2008] 3 SCR 265 At the outset, it is appropriate to refer to the words of Judson J. for this Court in Commissioner of Patents v. [read post]
14 Mar 2014, 1:02 pm
., Sanofi-Aventis US LLC, Sanofi-Aventis US Inc., and Sanofi-Synthelabo Inc. in a claim of strict product liability, manufacturing defect, negligence, and failure to warn. [read post]
19 Dec 2012, 8:51 pm
” Sanofi-Synthelabo v. [read post]
9 Nov 2011, 9:59 pm
By Donald Zuhn -- In an appeal decided last month, the Federal Circuit reversed a decision by the District Court for the Southern District of New York awarding prejudgment interest to Plaintiffs-Appellees Sanofi-Aventis, Sanofi-Synthelabo, Inc., and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership ("Sanofi"); affirmed the District Court's denial of a motion for leave to file a supplemental answer, affirmative… [read post]
13 Oct 2011, 7:45 pm
" Ecolab, 569 F.3d at 1352 (quoting Sanofi-Synthelabo v. [read post]
24 Aug 2011, 9:00 pm
Sanofi-Synthelabo v. [read post]
10 May 2011, 1:29 pm
" Sanofi-Synthelabo v. [read post]
18 Feb 2011, 11:47 am
The defendants in both sets of actions were Sanofi Aventis and Sanofi-Synthelabo, Inc., Bristol-Myers Squibb Company and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership (collectively “Sanofi”) and Apotex Corporation (“Apotex”). [read post]
15 Feb 2011, 9:27 am
Michael Davitz, Partner at Axinn, Veltrop & Harkrider and Practice Center Contributor, recently sent in this article he wrote with colleague’s Drew Schulte and Jia Li discussing the Patent Prosecution Highway and the value that can be achieved for those practitioners willing to explore the new program. [read post]
4 Nov 2010, 6:14 am
And although a reference must be enabling to be anticipatory, see Sanofi-Synthelabo, 550 F.3d at 1082, unlike enablement under § 112, a reference need not, as AstraZeneca suggests, demonstrate utility or efficacy to be enabling in the context of § 102, see In re Gleave, 560 F.3d 1331, 1335-36 (Fed. [read post]
2 Nov 2010, 1:40 am
Genentech, Inc. v. [read post]
24 Sep 2010, 1:15 pm
Sanofi-Synthelabo v. [read post]
24 Sep 2010, 1:06 pm
”Sanofi-Synthelabo v. [read post]
7 Sep 2010, 8:52 am
Teleflex Inc. [read post]
